MENA BIOLOGICS & BIOSIMILARS MARKET ANALYSIS

MENA Biologics & Biosimilars Market, By Product Type (Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin (Epoetin Alfa (Procrit, Epogen), Darbepoietin Alfa (Aranesp), Epoetin Alfa-epbx (Retacrit)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP))), By Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), By Geography (Gulf and Egypt)

MENA Biologics & Biosimilars Market: Key Developments

On February 7, 2023, Saudi Pharmaceutical Industries & Medical Appliances Corporation announced the details of its revamped 5-year strategy. The strategy focused on building the National Champion in the Saudi pharma industry by capitalizing on long-term opportunities offered by the conducive market outlook, while aiming at improving the wellbeing of patients and benefiting all groups of the Company’s stakeholders in the long-term.
On July 13, 2020, CanSino Biologics, a China-based vaccine developer, announced its plans for a Phase III trial of its experimental COVID-19 vaccine in Russia, Brazil, Chile, and Saudi Arabia.

MENA Biologics & Biosimilars Market: Key Trends

Increasing inorganic activities such as agreements: The market players are focused on adopting strategies such as agreements to gain a strong foothold in the region. For instance, in November 2022, Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, announced a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd. conducts worldwide marketing, sales, and distribution of biological medicines for CT-P43 (ustekinumab). CT-P43 is a monoclonal antibody that is a proposed biosimilar to Janssen’s Stelara. Under the terms of the agreement, Hikma will have exclusive rights to commercialize CT-P43 in all of its MENA markets, and Celltrion Healthcare will develop, manufacture, and supply CT-P43 to Hikma.

MENA Biologics & Biosimilars Market Report Snapshots